The high prevalence of genetic diseases resulting from gross deletions has highlighted a need for a quick, simple, and reliable method of genotyping these mutations. Here, we developed a novel strategy for applying TaqMan allelic discrimination to accurately genotype 3 different large deletions in a high-throughput manner. Allelic discrimination has previously been used to genotype frame shift and point mutations, and small insertions or deletions six base pairs in length, but not large deletions. The assays designed here recognize a 2502 base pair deletion in the Nebulin (NEB) gene that results in Nemaline Myopathy, a 308,769 base pair deletion in the Gap Junction Protein, beta 6 (GJB6) gene that causes Hearing Loss, and a 6433 base pair deletion in the Mucolipin 1 (MCOLN1) gene responsible for causing Mucolipidosis IV Disease. This methodology may also be successfully applied to high throughput genotyping of other large deletions.
Introduction
Due to the high demand for quick and accurate diagnosis of numerous genetic diseases, many advances have been made in terms of detecting mutations and determining genotypes [1] . One of the most efficient ways to analyze genotypes is through the TaqMan allelic discrimination, which has frequently been used to characterize single nucleotide polymorphisms (SNPs). There are many diseases that result from large deletions, however, that until now have only been detectable by copy number analysis, multiplex ligation-dependent probe amplification [2] , or direct sequencing [3] , but these methods can be time consuming, expensive, and difficult to interpret and apply in studies requiring high throughput. An alternative approach would be to use TaqMan allelic discrimination technology, similar to how it has been applied to genotype SNPs, to determine the genotypes of gross deletion mutations.
Although TaqMan technology has been applied before to an insertion/deletion polymorphism of 276 base pairs in length [4] , there are genetic diseases that result from much larger deletions such as Nemaline Myopathy or Mucolipidosis IV. In the present study, publically available primer and probe design software was used to design TaqMan assays that operate under universal conditions and could successfully genotype three different gross deletions ranging in size from 2.5 to 309 kilobases.
Results
The first mutation analyzed was the 2,502 base pair deletion in the NEB gene (Fig. 1A) . During the initial analysis, (when the two assays were individually used) five different gDNA samples and a no template control were evaluated. As shown in Fig. 1B , four of the five gDNA samples amplified with the NEB wild type assay (NEBwt). Similarly, the NEB deletion assay (NEBdel) showed that two gDNA samples had amplified and three had not. The combination of the two independent results could be used to distinguish between homozygous wild type, heterozygous, and homozygous mutant genotypes. It became apparent that one gDNA sample had amplified in both plots, while the remaining four gDNA samples had only amplified in one of the plots. These results were consistent with previous characterization of the genotypes of each sample. The sample that had amplified in both plots was the heterozygous carrier sample, while the wild type samples only amplified when the wild type assay was used and the homozygous affected sample only amplified when the deletion assay was used. Due to the success of the individual assays, the two assays were combined and run against the same gDNA samples and no template control. After combining the assays, the allelic discrimination plot showed three distinct clusters representing the three different genotypes. These three clusters were representative of the samples, with the three wild type samples gathered together and clearly separated from the heterozygous carrier sample, which was in turn separated from the homozygous affected sample. The accuracy of the combined assay prediction, based on the previous knowledge of the samples and the previous uses of the assays individually, was 100%.
The next mutation analyzed was the 308,769 base pair deletion in the GJB6 gene ( Fig. 2A) . During the initial analysis, four gDNA samples were used along with a no template control. As indicated in Fig. 2B , the GJB6 wild type assay (GJB6wt) revealed four amplified gDNA samples, while the GJB6 deletion assay (GJB6del) had only one amplified sample. Inspection confirmed that the heterozygous carrier sample was the sample that had amplified for both assays, and that the wild type samples had only amplified when exposed to the wild type assay. The assays were then combined and tested on the original samples, as well as two additional heterozygous carrier samples. Once again, the allelic discrimination plot showed a distinct separation between the two different genotypes, and had an accuracy of 100%.
Finally, the 6.4 kb deletion in the MCOLN1 gene was analyzed (Fig. 3A) . This mutation was particularly hard to design a deletion assay for because it had many short tandem repeats in its sequence. Both a wild type and a deletion assay were designed and individually tested on three wild type, two heterozygous carriers, and a no template control sample. The success of the individual assays (as shown in Fig. 3B ) led the two assays to be combined and tested on the same samples. The combined assays were again able to genotype the samples with an accuracy of 100%.
In order to further validate the accuracy of the assays, a blind study was performed for the NEB deletion (Fig. 4) . Twenty new gDNA samples were extracted from new blood samples of which the genotype was not provided. After running the wild type and deletion assays for the NEB deletion in combination, two distinct clusters were observed, with ten of the blind samples falling into the heterozygous carrier cluster and ten falling into the homozygous wild type cluster. Controls for all three possible genotypes, along with a no template control, were also included in the study. All of the samples were run in duplicate in Allelic discrimination plots for wild type, deletion, and combination assays. For the wild type assay, the heterozygous carrier and wild type samples amplified. For the deletion assay, the heterozygous carrier and homozygous affected samples amplified. When the wild type and deletion assays were combined in one reaction, the various genotypes were separated on one plot into individual clusters. The wild type sequence was used as the VIC probe and the deletion sequence was used as the FAM probe. NTC = No template control. Fig. 2B : Allelic discrimination plots for wild type, deletion, and combination assays. For the wild type assay, the heterozygous carrier and wild type samples amplified. For the deletion assay, the heterozygous carrier amplified. When the wild type and deletion assays were combined in one reaction, the various genotypes were separated on one plot into individual clusters. The wild type sequence was used as the VIC probe and the deletion sequence was used as the FAM probe.
order to ensure that the correct genotype was called. Two replicates representing two different samples did not cluster, but remained in between the homozygous wild type and heterozygous carrier clusters, making their call "Undetermined." Since both samples also had a replicate that did cluster, however, genotypes were still able to be assigned to these samples. The original genotypes for the blind samples were then obtained, revealing that all twenty samples had been correctly genotyped, making this method 100% accurate.
Finally, in order to ensure that this procedure was applicable to high-throughput processes, a carrier frequency study was also done for the NEB deletion (Fig. 5) . One thousand one hundred and forty-six gDNA samples obtained from individuals of Ashkenazi Jewish heritage were plated in duplicate and genotyped using real time PCR and TaqMan allelic discrimination. The homozygous wild type and heterozygous carrier samples clearly separated from each other, allowing the samples to be genotyped. Fifteen samples were identified as being heterozygous carriers, revealing a carrier frequency of 1.3% (15/1146). This is comparable to the published carrier frequency of 0.92% (1/108) [5] .
These results therefore indicate that not only can TaqMan SNP assays be used to correctly genotype gross deletion mutations, but that combining the deletion and wild type assays can allow for a single, accurate, genotyping reaction to take place. Furthermore, the carrier frequency study also proves that these assays are amenable to highthroughput procedures.
Discussion
When originally genotyping the above deletions, two TaqMan assays were designed with one targeting the wild type sequence and the other the deletion sequence. The two assays were individually run as two separate reactions, and afterwards the two amplification plots were compared to determine the genotypes of the samples. For these assays, the gDNA of a heterozygous carrier would amplify for both assays, but the wild type gDNA would only amplify in the wild type sequence assay and homozygous affected gDNA would only amplify in the deletion sequence assay. This method, while accurate and more Fig. 3B : Allelic discrimination plots for wild type, deletion, and combination assays. For the wild type assay, the heterozygous carrier and wild type samples amplified. For the deletion assay, the heterozygous carrier amplified. When the wild type and deletion assays were combined in one reaction, the genotypes were separated on one plot into individual clusters. The wild type sequence was used as the VIC probe and the deletion sequence was used as the FAM probe. Fig. 4 . Blind Study for NEB deletion. Allelic discrimination plot showing the genotypes for twenty blind gDNA samples. The blind samples are depicted in gray, while the control samples are in black. All of the blind samples were plated in duplicate. Two of the samples had individual replicates that did not cluster, which were therefore called "Undetermined." Since these two samples had a replicate that did cluster, however, a genotype was still assigned for the samples. Of the twenty samples, ten were homozygous wild type and ten were heterozygous carriers.
resourceful than many alternative procedures, was not as efficient as it could be because it required using twice the amount of gDNA as a normal SNP assay would require, and it took more preparation time. By combining the wild type and deletion assays for use in one reaction, less gDNA is needed and the data can appear on one amplification plot, making the results easier to interpret. Importantly, the combined wild type and deletion assays act in exactly the same manner as normal SNP genotyping assays.
The benefit of using TaqMan assays to genotype gross deletions extends to numerous endeavors, with the primary advantage being that the TaqMan assays are more efficient in genotyping. Alternative methods for characterizing deletion mutations, such as multiplex ligation-dependent probe amplification and DNA sequencing, require the use of electrophoresis for analysis, which is not only time consuming, but can also be difficult to interpret. Furthermore, TaqMan assays such as these can be applied to carrier frequency studies where a gross deletion is the mutation causing the genetic disease. Due to the ability of TaqMan assays to be applied to high throughput screening, these assays can replace the need for copy number analysis for certain mutations, and instead allow for a qualitative approach.
The incorporation of TaqMan deletion assays, such as the ones featured here, into genetic screens will lead to more proficient and accurate genotype diagnoses for potential carriers. For instance, the three deletion mutations highlighted in this paper are very prevalent in the Ashkenazi Jewish population and therefore screened for often. Haplotype testing using microsatellite markers has indicated a founder effect for both the NEB and the GJB6 deletion in the Ashkenazi Jewish population with a carrier frequency of 1 in 108 [5] for the first and a homozygous affected rate of 0.5% for Israeli Ashkenazi Jews for the latter [6] . Similarly, by using a TaqMan platform to generate cycle threshold (Ct) and relative fluorescence unit values, an allele mutation rate of 0.24% was found in the Ashkenazi Jewish population for the MCOLN1 deletion [7] . The high prevalence of these specific mutations necessitates not only the development of the above TaqMan deletion assays, but also the knowledge that the productions of such assays are feasible in general.
Materials and methods

Population
The gDNA used in this study was obtained from individuals of Ashkenazi Jewish ancestry. The gDNA was extracted from blood, and the concentrations were obtained via Nanodrop (Thermo Fisher Scientific Inc., Wilmington, DE, USA). The gDNA was then normalized to 5 ng/μL.
Experimental design
The goal of this research was to determine if TaqMan SNP assays (Applied Biosystems Inc.
[AB], Carlsbad, CA, USA) could be used to successfully genotype large deletions by discriminating homozygous wild type, heterozygous carrier, and homozygous affected genotypes.
Each pair of assays was tested on either known heterozygous carrier gDNA and/or homozygous affected gDNA that was specific for the disease the assay was designed to detect. The number of samples for each assay varied based on the availability of the gDNA. In all of the tests, three wild type gDNA controls, as well as a no template control, were always included. The gDNA was plated in duplicate in 384 well plates along with TaqMan Master Mix (AB) and the pairs of assays, resulting in a final volume of 5 μL. 10 ng of template DNA was used per reaction. The plates were centrifuged for 1 minute, sealed, and then run in duplex real time PCR reactions using FAM and VIC as the detector probes. After the real time PCR was finished, allelic discrimination analysis was performed using SDS 2.3 software (AB). This allowed the assay performance to be evaluated.
For the blind study, twenty gDNA samples were extracted from twenty blood samples and then normalized to 5 ng/μL. The genotypes for these samples were not known throughout the blind study. In addition to the twenty samples of unknown genotype, three wild type samples, one heterozygous carrier, and one homozygous affected gDNA sample, as well as a no template control, were run as controls. The gDNA was plated in duplicate in 384 well plates along with TaqMan Master Mix (AB) and the pair of assays, resulting in a final volume of 5 μL. 10 ng of template DNA was used per reaction. The plates were centrifuged for 1 minute, sealed, and then run in duplex real time PCR reactions using FAM and VIC as the detector probes. After the real time PCR was finished, allelic discrimination analysis was performed using SDS 2.3 software (AB) to genotype the samples. Genotypes were assigned to the twenty blind samples based on their clustering. The samples' original genotypes were then revealed for comparison. All of the samples were correctly assigned the right genotype.
For the carrier frequency study, 1 μL gDNA was plated in duplicate in 384 well plates containing 3 μL of water. The gDNA was not normalized prior to plating. The plates were then dried and refrigerated until needed. The wild type and deletion assays were then added at equal volume, along with TaqMan Master Mix (AB) and water to bring the final volume to 5 μL. The plates were centrifuged for 1 minute, sealed, and then run in duplex real time PCR reactions using FAM and VIC as the detector probes. After the real time PCR was finished, allelic discrimination analysis was performed using SDS 2.3 software (AB) and results were compiled using TaqMan Genotyper Software (AB).
Assay design
As indicated in Table 1 , two assays each were originally required for the analysis of the three deletion mutations. A pair of assays was designed for a 2502 base pair deletion [8] that occurs in the NEB gene and results in Nemaline Myopathy. Another pair of assays was produced for a 308,769 base pair deletion [9] in the GJB6 gene that results in Hearing Loss [10] . Finally, two assays were designed to detect a 6433 base pair deletion [11] that occurs in the MCOLN1 gene and results in Mucolipidosis IV Disease [12] . The assays were designed by using NCBI to search for the full sequence of the gene (FASTA). Once the location of the breakpoint was found, roughly two hundred base pairs upstream and downstream of the deletion breakpoint were selected and put into Repeat Masker to mask for the repeats (Institute for Systems Biology, Seattle, WA, USA). The original selected sequence was then put into the NCBI Blast site (SNP Flanks) so that SNPs could be masked.
The primers for the wild type assays were designed by taking either the first nucleotide downstream of the first breakpoint or the first nucleotide upstream of the second breakpoint, and giving this nucleotide a false minor allele (which could be any of the remaining three options for a DNA base). This was done in order to make the assay a SNP assay so that allelic discrimination could be performed. The primers for the deletion assays were designed by selecting the nucleotide one basepair upstream of the first breakpoint or the nucleotide one basepair downstream from the second breakpoint as the minor allele and giving it a false major allele. Notably, since one allele was artificial in both of the assays, the wild type assay only utilized the VIC probe and the deletion assay only utilized the FAM probe. The assays were then made in File Builder software (AB).
After the initial success of using the two assays individually to correctly genotype the large deletions, the assays were combined. This combination utilized both the FAM and VIC probes to genotype the large deletions in one reaction
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